BioSpace News Archive

Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today announced that Phil Pang, M.D., Ph.D., chief medical officer of Vir will present at the Cantor Global Virtual Healthcare Conference on Tuesday, September 15 th at 8:20 am PT/ 11:20 am ET. A live webcast of the presentation can be accessed under Events & Presentations in the Investors section of

Sonoma Pharmaceuticals and Te Arai BioFarma Announce Launch of Two New Microcyn ® Technology Products in Australia – Nasocyn ® Nasal Care and Oracyn ® Oral Care

SonoScape Medical Corporation introduced its new generation high-end ultrasound systems: the ELITE series, integrating artificial intelligent solutions, advanced features, and remarkably improved system processing capability.

Mark G. Mishek has transformed pioneering addiction treatment nonprofit into a 21st Century healthcare leader; will serve until successor is hired

Genova Diagnostics has partnered with Rocky Mountain Analytical, a subsidiary of LifeLabs and leading provider of naturopathic and functional medicine, in a new distribution agreement.

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, announced today that it has closed its previously announced registered direct offering to certain institutional investors of 8,865,000 shares of common stock at a price of $0.79 per share.

QHR Health, the largest healthcare shared services company for non-urban hospitals and health systems nationwide, announced today the acquisition of revenue cycle service provider, Resolution. BRENTWOOD, Tenn. , Sept. 9, 2020 /PRNewswire/ -- QHR Health, the largest healthcare shared services company for non-urban hospitals and health systems nationwide, annou

NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, announced the formation of the GeoMx Translational Leadership Network.

The proposed agreement is intended to provide a supply of 200 million doses and an option to purchase additional 100 million doses, with deliveries starting by the end of 2020, subject to regulatory approval

Eli Lilly and Company announced that Patrik Jonsson, senior vice president and president of Lilly Bio-Medicines, is being named to the new role of senior vice president, president of Lilly USA, and Chief Customer Officer.